BridgeBio has partnered with Bristol Myers Squibb to evaluate BBP-398 and OPDIVO for patients with advanced solid tumors with KRAS mutations, aiming to provide new treatment options.

Bristol-Myers Squibb

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

BridgeBio

Biopharma and biotechnology companies that develop precision medicine drugs based on novel disease biomarkers present in multi-omic patient population data and genetic insights.

The Pritzker Organization

Tao Capital Partners

DNS Capital

IMIDomics

Bristol Myers Squibb has exercised its option under a global neuroscience research and development collaboration with Prothena Corporation plc to obtain an exclusive U.S. license for PRX005, an anti-tau antibody aimed at treating Alzheimer's disease.

Longevity Tech

Prothena

Companies in the neurotechnology sector that develop tools such as neuroimaging and neurostimulation devices; pharmaceutical drugs and therapies aimed at treating age-related neurological conditions

Eisai and Bristol Myers Squibb have partnered for the global development and commercialization of MORAb-202, an ADC targeting FRα-positive solid tumors.

Eisai

Exelixis collaborates with Bristol Myers Squibb for phase 1b trial STELLAR-002, evaluating XL092 in combination with various immuno-oncology therapies for advanced solid tumors.

Exelixis

Google Ventures

Novartis Venture Fund

The Column Group

Peregrine Ventures

OUP (Osage University Partners)

Takeda Ventures

AbbVie Biotech Ventures

Deerfield

U.S. Venture Partners

Euclidean Capital

Johnson & Johnson Innovation – JJDC

Monashee Investment Management

Avego Bioscience Capital

Ribon Therapeutics

Spring Mountain Capital

Elm Street Ventures

Life Science Angels

Harrington Discovery Institute at University Hospitals

Allyx Therapeutics

The collaboration will leverage AI to speed the discovery of drug candidates in several therapeutic areas, including oncology and immunology. This deal is an expansion of a collaboration that originated in 2019 between Exscientia and Celgene before BMS acquired Celgene. Exscientia will handle AI design and experimentation for drug discovery.

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

Exscientia

Biotechnology companies that have integrated AI as a core component of their in-house drug development process. They typically have a few in-house drug development programs, and also collaborate with pharma companies to develop certain drugs.

ARCH Venture Partners

Huizenga Capital Management

Trinitas Capital

Magnetic Ventures

HiberCell

Polaris Partners

General Catalyst

Adage Capital Management

Kaiser Permanente

General Atlantic

Tiger Global Management

Merck Global Health Innovation Fund

LabCorp

Refactor Capital

KdT Ventures

Bienville Capital

D1 Capital Partners

Biospring Partners

PathAI

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies to identify biomarkers (measurable biological signs used to determine disease progression) and predict drug response. 

DarwinHealth collaborates with Bristol-Myers Squibb on the Novel Cancer Target Initiative (NCTI) to identify novel cancer targets across various tumor subtypes.

DarwinHealth

University of Birmingham partners with Evotec SE and Bristol Myers Squibb in beLAB1407, aiming to accelerate drug discovery and advance breakthrough therapies with a $20 million investment.

University of Birmingham

Syngene International extends its research collaboration with Bristol Myers Squibb until 2030, expanding drug discovery efforts across various domains and adding a new 50,000 sq. ft. laboratory space.

Syngene

Farallon Capital Management

Novo Holdings

Casdin Capital

BlackRock

Marshall Wace

Pivotal bioVenture Partners

GT Healthcare Capital Partners

SoftBank Vision Fund

Mubadala Capital Ventures

Laurion Capital Management

Hongyou Investment

PsiOxus Therapeutics has updated its collaboration with Bristol Myers Squibb to assess the safety and efficacy of combining PsiOxus' tumor re-engineering platform with Bristol Myers Squibb's Opdivo® (nivolumab) for late-stage cancer patients. The collaboration involves combining Opdivo with PsiOxus' NG-641, a tumor re-engineering product utilizing PsiOxus' T-SIGn platform, aimed at addressing the immune suppressive tumor microenvironment in refractory tumors.

Akamis Bio

Novartis

MPM Capital

EcoR1 Capital

Vida Ventures

Octagon Capital Advisors

TCG Crossover

Radioactive materials open up new pathways in patient treatment and medication

Radiopharmaceuticals

Aktis Oncology

Companies that use radioactive isotopes to develop medication for the treatment of diseases in patients.

Evotec

BlackRock Innovation Capital

InHarv Partners

LabCorp Venture Fund

Targeting complex diseases with complex molecules

Large-molecule Therapeutics

Presage Biosciences

Companies that develop large molecules that can be used to target specific RNA molecules in the body, either to silence or replace them

Astellas Venture Management

F2 Ventures

Kite Pharma

Taiho Ventures

Novartis Institutes for Biomedical Research

The Pags Group

RNA Therapeutics

Orna Therapeutics

Companies focused on other RNA-based therapies using approaches such as tRNA, circRNA, lncRNA, and saRNA to develop treatments targeting specific RNA molecules to regulate gene expression.

Bristol Myers Squibb partners with the American Music Therapy Association and Ben Platt to launch MS in Harmony, a digital platform for MS patients using music therapy. T

American Music Therapy Association

Molecular Templates partners with Bristol Myers Squibb for novel oncology therapies using ETB platform

Molecular Templates

Bristol Myers Squibb and The Rockefeller University have entered into a global exclusive licensing agreement for a novel monoclonal antibody duo treatment to neutralize SARS-CoV-2.

The Rockefeller University

Illumina and Bristol Myers Squibb expand partnership to develop liquid biopsy diagnostic tools for precision oncology, focusing on TSO 500 ctDNA and MSI companion diagnostic.

Illumina

Companies that develop an in-vitro medical device or imaging tools and tests that identify genetic mutations for both diagnostic (nature of the disease) and prognostic (likely course of the disease) purposes, allowing providers to match a patient to a specific drug or therapy.

Avidity collaborates with MyoKardia, a Bristol Myers Squibb subsidiary, to explore the potential of AOCs in cardiac tissue using MyoKardia's genetic cardiomyopathy platform, including target discovery and disease models.

Avidity Biosciences

ArsenalBio partners with Bristol Myers Squibb to develop next-gen T cell therapies for solid tumors.

ArsenalBio

Atlas Venture

Fidelity

Invus

OrbiMed

Omega Funds

Biotechnology Value Fund

HealthCor Partners

Cowen Healthcare Investments

Surveyor Capital

Logos Capital

Ikena Oncology

Schrödinger, Inc. partners with Bristol Myers Squibb to develop and commercialize therapeutics across various diseases, leveraging advanced computational platforms and drug discovery capabilities.

Schrödinger

Bristol Myers Squibb completes USD13.1 billion acquisition of MyoKardia, gaining access to potential cardiovascular breakthrough mavacamten.

MyoKardia

To develop treatments for neurodegenerative disorders. Insitro will use its platform to create induced pluripotent stem cell-derived disease models for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

Insitro

Maverick Ventures

Ysios Capital

Sphera Funds Management

Seventure Partners

HBM Healthcare Investments AG

Cormorant Asset Management

Canica

Hadean Ventures

Janus Henderson Investors

Sunstone Life Science Ventures

Soleus Capital

EIR Ventures

Asymmetry Capital Management

Galecto

Bristol Myers Squibb has acquired Forbius, a company specializing in biotherapeutics for cancer and fibrotic diseases, with a focus on TGF-beta inhibitors.

Forbius

Dragonfly Therapeutics partners with Bristol Myers Squibb to develop novel immunotherapies for multiple sclerosis and neuro-inflammation targets, with Bristol Myers Squibb gaining licensing options and making an initial payment of USD 55 million.

Dragonfly Therapeutics

ArcherDX, Inc. collaborates with Bristol Myers Squibb to explore the potential of minimal residual disease (MRD) detection using Personalized Cancer Monitoring assays in cancer patients undergoing immunotherapy.

ArcherDX

Pfizer Venture Investments

Biogen

Section 32 Alexandria Venture Investments

Samsara BioCapital

Autobahn Therapeutics

BMS entered into a multi-target discovery collaboration with Repare Therapeutics to leverage the latter's SNIPR technology to identify novel oncology targets.

Reinventing gene therapies with next-generation technologies

Human Gene Editing

Repare Therapeutics

Companies that develop novel therapeutics based on the CRISPR/Cas9 gene-editing technology

This partnership aims to develop high-performance recombinant antibodies targeting various human cell targets.

Recombinant Antibody Network

Companies that develop large molecules that combine the targeting ability of monoclonal antibodies with the cytotoxic effects of chemotherapy drugs

University of California, San Francisco

This alliance aims to advance the development of cutting-edge recombinant antibodies against a wide array of human cell targets.

The University of Chicago

GRYT Health and Bristol Myers Squibb partner to develop the COVID Advocacy Exchange, uniting patient advocacy organizations in virtual platform.

GRYT Health

bluebird bio and Bristol Myers Squibb amend agreement to streamline commercialization of idecabtagene vicleucel (ide-cel; bb2121) in the U.S., focusing efforts on bringing the BCMA-directed CAR T cell therapy to patients.

Bluebird Bio

NeoImmuneTech, Inc. partners with Bristol Myers Squibb to evaluate NT-I7 and Opdivo combination in Phase 2 study for advanced gastric/esophageal cancers, aiming to establish safety and anti-tumor activity.

NeoImmuneTech

Pontifax

Colt Ventures

Nextech Invest

NS Investment

Hunt Investment Group

Silverback Therapeutics

Voluntis and Bristol-Myers Squibb are partnering to develop digital therapeutic solutions for cancer patients. Leveraging Voluntis' platform, the collaboration aims to provide a mobile app for symptom management and remote monitoring.

Membership-based, non-insurance healthcare companies helping maintain a steady state of well being.

Preventive Healthcare

Voluntis

Companies offer B2B and D2C evidence-based treatments delivered via software programs to prevent and manage a variety of chronic conditions.

To expand the joint development plan for bempegaldesleukin (bempeg) plus Opdivo (nivolumab) into new registrational trials for various types of cancer. The collaboration aims to develop potential combination therapies to meet the needs of cancer patients.

Nektar Therapeutics

WindMIL Therapeutics collaborates with Bristol-Myers Squibb to assess the safety and efficacy of marrow-infiltrating lymphocytes (MILs™) alongside nivolumab in advanced non-small cell lung cancer patients, focusing on those refractory or relapsed on anti-PD-1 therapy.

WindMIL Therapeutics

BioMotiv and Bristol-Myers Squibb form a strategic partnership to develop innovative therapies, with Bristol-Myers Squibb becoming a limited partner of BioMotiv.

BioMotiv

Bristol-Myers Squibb (BMS) collaborates with UCD School of Chemical & Bioprocess Engineering through a strategic partnership, providing guest lectures by experts in bioprocessing technology from BMS Cruiserath campus.

University College Dublin

Bristol-Myers Squibb Company has partnered with Ono Pharmaceutical and Bayer to assess the combination of regorafenib and nivolumab in MSS mCRC patients.

Bristol Myers Squibb

Featured Industries

Recent Updates

Bristol-Myers receives FDA approval for Breyanzi to treat non-Hodgkin lymphomas

VantAI signs USD 674 million GenAI deal with Bristol Myers Squibb

Terray Therapeutics and Bristol Myers collaborate to develop small-molecular therapeutics

BMS’ multiple myeloma drug Abecma approved in Japan

FDA delays decision on BMS-2seventy bio’s Abecma approval expansion application

Tempus collaborates with Bristol Myers Squibb for cancer research using AI

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless